Meta AnalysisID 2199
评估金雀花碱治疗戒烟的有效性：系统评价与Meta分析
CRD42022296780
The research question is structured according to the PICO criteria: -Population: Patients of any age, smokers -Intervention: Cytisine administered as monotherapy orally in any dose schedule -Comparator: Any pharmacologic
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2199
- Evidence Id
- 10757
- Core Evidence Id
- 10757
- Source Meta Analysis Id
- 2147
- Herb2 Meta Analysis Id
- HBMA002147
- Crd Id
- CRD42022296780
- Title
- Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: a systematic review and meta-analysis
- Review Question
- The research question is structured according to the PICO criteria: -Population: Patients of any age, smokers -Intervention: Cytisine administered as monotherapy orally in any dose schedule -Comparator: Any pharmacological intervention, placebo or psychological interventions for smoking cessation -Outcomes: • Smoking cessation, verified by self-report and / or biochemically at 6 months and 12 months • Incidence of adverse effects
- Study Type Included
- This review will be prepared following the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA). The search strategy will be agreed by the authors and replicable, obtaining all relevant studies. The review will be done in duplicate to establish the eligibility of the studies.One reviewer will screened the titles and abstracts of publications identified by the search. -Inclusion criteria: articles with original data from RCT examining the use of cytisine for smoking cessation. The search will not be restricted by language or status of publication -Exclusion criteria: a) repetitive data b) old published data for the same study c) unavailability of the complete report for reference in case of lack of clarity of information in the abstract
- Condition Being Studied
- Smoking is a chronic disease that generates 8 million premature deaths annually globally (1). It is one of the main causes of years of life lost or years lived with disability and is considered worldwide the main cause of preventable death (1) (2). Its treatment approach includes, among other strategies, increasing the accessibility to drug therapy, which is limited mostly in low- and middle-income countries. According to the results of the latest National Survey of Risk Factors carried out during 2018, the prevalence of smoking in Argentine is 22.2% (95% CI 21.1-23.1) (8). Its prevalence, morbidity and mortality in Argentine continue to be one of the highest in our region and it is even higher in people of lower socioeconomic status (8). These inequalities in health reflect the serious problem of equity in Argentine, constituting a vicious circle between the determinants of health, the determinants of poverty and diseases of our population (9). The results of recently published studies, some in low- and middle-income countries, that were not included in previous systematic reviews could provide relevant evidence on this intervention, which allows greater certainty for decision-making (10) (11) (12 ).
- Participant
- Inclusion criteria: Smokers of any age Exclusion criteria: Non smokers
- Animal
- Human Disease Modelled
- Intervention
- Cytisine is an alkaloid present in plants of the Fabacea family, such as the tree of the genus Laburnum anagyroides (golden rain), with a high affinity and partial agonist action on the nicotinic receptor alpha 4 beta2 (4) (5). Its synthesis as a low-cost drug for smoking cessation began in Bulgaria in 1964 (Tabex®), and later spread to other countries in Eastern Europe and Asia, where it is still marketed (6) (7). -Inclusion criteria: randomized controlled trials (RCT) examining the use of oral cytisine for smoking cessation in any dose schedule-Exclusion criteria: a) smoking cessation is not evaluated b) smoking cessation is not an outcome c) outcome measures are not reported in a usable form d) use of cytisine for conditions other than smoking cessation
- Comparator Control
- -Inclusion Criteria: Any pharmacological intervention, placebo or other intervention for smoking cessation. The pharmacological interventions considered will be Varenicline, Nicotine Replacement Therapies (NRT) and Bupropion. In addition, psychological interventions like cognitive behavioural therapy (CBT), motivational interviewing (MI), counselling, and telephone smoking cessation support will be included. -Exclusion Criteria: Alternative therapies for smoking cessation (including hypnosis, acupuncture or laser therapy)
- Main Outcome
- The purpose of this review will be to evaluated the scientific evidence available until March 2022 to summarize the existing evidence on the effectiveness and safety of Cytisine for smoking cessation, compared to other therapeutic strategies. -Primary outcome The primary outcome will be smoking cessation, verified biochemically at 6 and 12 months -Secondary outcome The secondary outcomes will be: a) Smoking cessation according to self-report at 6 and 12 months b) Incidence of adverse effects Measures of effect We will folow the intention-to-treat (ITT) principle, to assess the effect of intervention allocation, and maintains the benefit of the randomization. We will considered the smoking cesastion and adverse reactions (ARs) as categorical data, and determinate the relative risk (RR) with its respective 95% confidence interval (CI 95%). As an absolute measure, the Number Needed to Treat (NNT) will be determined as the inverse the Absolute Risk Reduction (ARR)
- Outcome Measure
- Additional Outcome
- Not applicable
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Alkaloids; Azocines; Humans; Quinolizines; Smoking Cessation; cytisine
- Contact
- Omar De Santi [email protected]
- Organisational Affiliation
- Hospital Nacional Profesor Alejandro Posadas-Centro Nacional de Intoxicaciones (CNI) [email protected]
- Funding Source
- None Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> None
- Other Selection Criteria
- Final Publication
- Omar De Santi, Vanina Greco , Cecilia Di Niro , et al. Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: a systematic review and meta-analysis. Authorea. January 31, 2023. DOI: 10.22541/au.167516104.43169121/v1 https://www.authorea.com/doi/full/10.22541/au.167516104.43169121/v1
- Same Topic Review
- Not applicable
- Published Protocol
- Review Type
- Language
- English
- Country
- Argentina
- Review Stage
- Review Completed not published
- First Submission Date
- 2021-12-18
- Registration Date
- 2022-01-19
- Anticipated Start Date
- 2022-01-22
- Anticipated Completion Date
- 2022-09-23
- Title Cn
- 评估金雀花碱治疗戒烟的有效性：系统评价与Meta分析
- Title En
- Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: a systematic review and meta-analysis
- Bilingual Status
- complete